PSNLPersonalis, Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +54% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 1.4% since the previous count, down from 10.7% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How PSNL is trading
Personalis, Inc. is +162% over the past year while the S&P 500 is +18%: 144 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +54%
vs 200-day average · a clear uptrend
- RSI (14)
- 43
RSI (14) · neutral
- Below its 52-week high
- 13%
Below its 52-week high
Details›
- Last close2026-10-09
- $16.00
- 1 monthS&P 500 +2.7%
- −2.1%
- 1 yearS&P 500 +18%
- +162%
- 5 yearsS&P 500 +88%
- −25%
- vs 50-day average$15.70
- +1.9%
- 52-week high
- $18.41
- 52-week low
- $5.04
- Annualised volatility
- 96%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$267K
| Year | Return |
|---|---|
| 2026 (year to date) | +101% |
| 2025 | +38% |
| 2024 | +175% |
| 2023 | +6.1% |
| 2022 | −86% |
| 2021 | −61% |
| 2020 | +236% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 4 of 7 | −3.5% |
| Feb | 7 | 2 of 7 | −4.0% |
| Mar | 7 | 0 of 7 | −15% |
| Apr | 7 | 3 of 7 | −3.9% |
| May | 7 | 3 of 7 | +10% |
| Jun | 7 | 5 of 7 | +8.0% |
| Jul | 8 | 4 of 8 | +24% |
| Aug | 8 | 5 of 8 | +12% |
| Sep | 8 | 1 of 8 | −6.6% |
| Oct | 8 | 3 of 8 | −0.48% |
| Nov | 7 | 3 of 7 | +1.5% |
| Dec | 7 | 5 of 7 | +14% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Diagnostics & Research
Ranks #21 of 21 by RyuScore